JP2024545222A5 - - Google Patents
Info
- Publication number
- JP2024545222A5 JP2024545222A5 JP2024535521A JP2024535521A JP2024545222A5 JP 2024545222 A5 JP2024545222 A5 JP 2024545222A5 JP 2024535521 A JP2024535521 A JP 2024535521A JP 2024535521 A JP2024535521 A JP 2024535521A JP 2024545222 A5 JP2024545222 A5 JP 2024545222A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- sirna
- antisense strand
- group
- nucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111545699 | 2021-12-16 | ||
| CN202111545699.6 | 2021-12-16 | ||
| PCT/CN2022/139500 WO2023109940A1 (zh) | 2021-12-16 | 2022-12-16 | 靶向lpa的sirna及缀合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024545222A JP2024545222A (ja) | 2024-12-05 |
| JP2024545222A5 true JP2024545222A5 (enExample) | 2025-12-26 |
Family
ID=86774879
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024535521A Pending JP2024545222A (ja) | 2021-12-16 | 2022-12-16 | ＬＰＡを標的とするｓｉＲＮＡ及び複合体 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250332190A1 (enExample) |
| EP (1) | EP4450624A4 (enExample) |
| JP (1) | JP2024545222A (enExample) |
| KR (1) | KR20240116539A (enExample) |
| CN (1) | CN118076738A (enExample) |
| CA (1) | CA3240604A1 (enExample) |
| TW (1) | TW202340465A (enExample) |
| WO (1) | WO2023109940A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119506275A (zh) * | 2023-08-22 | 2025-02-25 | 苏州炫景生物科技有限公司 | 抑制lpa基因表达的双链寡核苷酸及其应用 |
| AU2024280186A1 (en) | 2023-05-31 | 2025-12-04 | Tuojie Biotech (Shanghai) Co., Ltd. | Dsrna targeting lpa and use thereof |
| WO2025064821A2 (en) | 2023-09-21 | 2025-03-27 | Ionis Pharmaceuticals, Inc. | Compounds and methods for inhibiting lpa |
| WO2025082059A1 (zh) * | 2023-10-16 | 2025-04-24 | 润佳(上海)医药技术有限公司 | 经修饰的dsRNA、双链RNAi剂及其用途 |
| WO2025120571A1 (en) * | 2023-12-05 | 2025-06-12 | Janssen Biotech, Inc. | Compositions and methods to discover targeted oligonucleotide conjugates |
| WO2025252159A1 (zh) * | 2024-06-06 | 2025-12-11 | 大睿生物医药科技(上海)有限公司 | 调控LPA表达的dsRNA分子 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013299717B2 (en) | 2012-08-06 | 2018-06-28 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugated RNA agents and process for their preparation |
| CA2921162A1 (en) * | 2013-05-01 | 2014-11-06 | Ionis Pharmaceuticals, Inc. | Conjugated antisense compounds and their use |
| JOP20160211B1 (ar) * | 2015-10-01 | 2021-08-17 | Arrowhead Pharmaceuticals Inc | تراكيب وأساليب لتثبيط تعبير جيني للـ lpa |
| AU2017296195A1 (en) * | 2016-07-11 | 2019-01-24 | Translate Bio Ma, Inc. | Nucleic acid conjugates and uses thereof |
| WO2019204668A1 (en) * | 2018-04-18 | 2019-10-24 | Casebia Therapeutics Limited Liability Partnership | Compositions and methods for knockdown of apo(a) by gene editing for treatment of cardiovascular disease |
| CN111378655B (zh) * | 2018-12-28 | 2024-03-19 | 苏州瑞博生物技术股份有限公司 | 抑制CTGF基因表达的siRNA、含有该siRNA的药物组合物及其用途 |
| CN112876534B (zh) * | 2019-11-29 | 2024-02-09 | 苏州瑞博生物技术股份有限公司 | 肝靶向化合物及缀合物 |
| US20230201361A1 (en) * | 2020-01-11 | 2023-06-29 | Oncolmmunin, Inc. | Targeted and localized in vivo delivery of oligonucleotides |
| WO2021254360A1 (zh) | 2020-06-16 | 2021-12-23 | 上海拓界生物医药科技有限公司 | 一种碳水化合物分子簇及其制备方法和医药用途 |
| TW202535432A (zh) * | 2020-08-05 | 2025-09-16 | 美商戴瑟納製藥股份有限公司 | 抑制lpa表現之組合物及方法 |
| WO2022121959A1 (zh) * | 2020-12-09 | 2022-06-16 | 纳肽得有限公司 | siRNA分子及其在治疗冠状动脉疾病中的应用 |
| CN116801886B (zh) * | 2021-09-18 | 2024-12-06 | 成都心正合医药科技有限公司 | Lpa抑制剂及其用途 |
| CN114703184B (zh) * | 2022-03-11 | 2024-06-18 | 厦门甘宝利生物医药有限公司 | Lpa抑制剂及其用途 |
| CN115851723B (zh) * | 2022-10-24 | 2023-10-03 | 厦门甘宝利生物医药有限公司 | 一种抑制lpa基因表达的rna抑制剂及其应用 |
-
2022
- 2022-12-16 CN CN202280067981.4A patent/CN118076738A/zh active Pending
- 2022-12-16 EP EP22906685.7A patent/EP4450624A4/en active Pending
- 2022-12-16 US US18/719,828 patent/US20250332190A1/en active Pending
- 2022-12-16 TW TW111148548A patent/TW202340465A/zh unknown
- 2022-12-16 WO PCT/CN2022/139500 patent/WO2023109940A1/zh not_active Ceased
- 2022-12-16 KR KR1020247022570A patent/KR20240116539A/ko active Pending
- 2022-12-16 JP JP2024535521A patent/JP2024545222A/ja active Pending
- 2022-12-16 CA CA3240604A patent/CA3240604A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018529732A5 (enExample) | ||
| AU2016331084B2 (en) | Compositions and methods for inhibiting gene expression of LPA | |
| JP2025027008A5 (enExample) | ||
| JP2024081668A5 (enExample) | ||
| JP6752151B2 (ja) | 遺伝子サイレンシングにおいて低下したｏｆｆ−ｔａｒｇｅｔ効果を有するｕｎａオリゴマー | |
| JP2023145620A5 (enExample) | ||
| JP2021518125A5 (enExample) | ||
| JP2023103244A5 (enExample) | ||
| JP2020188756A5 (enExample) | ||
| JP2017532038A5 (enExample) | ||
| JP2023502038A5 (enExample) | ||
| JP2021522841A5 (enExample) | ||
| JP2022502055A5 (enExample) | ||
| JP2020533334A5 (enExample) | ||
| JP2017535552A5 (enExample) | ||
| JP2024524330A5 (enExample) | ||
| IL277970B2 (en) | Oligomeric compounds comprising modified oligonucleotides and conjugated groups for use in the treatment of end-stage renal disease, chronic kidney disease and coronary artery disease | |
| JP2018530529A5 (enExample) | ||
| JP2024531728A5 (enExample) | ||
| JP2023514336A5 (enExample) | ||
| JPH09506770A (ja) | ｃ−ｅｒｂＢの発現が関与する疾患を予防及び治療するためのアンチセンス核酸 | |
| JP2025500860A5 (enExample) | ||
| JP2024538859A5 (enExample) | ||
| JP2022518384A5 (enExample) | ||
| JP2024546667A5 (enExample) |